Key Takeaways
How to Help Someone With Addiction: What the Evidence Supports
Any answer to how to help someone with addiction starts with the treatment gap. In 2025, 47.2 million people ages 12 and older in the U.S. needed substance use treatment, and only 16.0% of them received any, according to the National Survey on Drug Use and Health (NSDUH)[1]. That left 39.6 million people with a past-year substance use disorder outside treatment[1].
Four approaches have direct research or federal guidance behind them: conversations that avoid confrontation and stigmatizing labels[5][6], structured family training known as CRAFT[2], naloxone on hand when opioids are involved[3], and knowing which treatments work, including medications for opioid use disorder[7].
This article covers drug use as well as alcohol. For drinking specifically, see how to help someone with an alcohol addiction; for how common addiction is by age, state and group, see the substance use disorder data page.
People ages 12+ who needed substance use treatment in 2025 and received it
That was 7.6 million of the 47.2 million people who needed treatment. The other 84.0%, or 39.6 million people, received no substance use treatment in the past year.
"16.0% (or 7.6 million people) received substance use treatment in the past year"
Why Most People With Addiction Don't Get Treatment
NSDUH asks people who felt they needed substance use treatment but did not get it to explain why. In 2025, the most common answer, given by 82.5%, was that they thought they should be able to handle their alcohol or drug use on their own[1].
Readiness came next: 68.4% were not ready to stop or cut back, and 67.7% were not ready to start treatment[1]. Practical and social barriers followed, including worry about what people would think (41.4%), not knowing how or where to get treatment (40.5%) and cost (39.2%)[8].
Another 34.9% thought bad things would happen if people knew they were in treatment, such as losing a job, home or children[8].
The leading reasons concern readiness and self-reliance more than access. That is the situation family-based programs were built for: CRAFT was tested specifically on engaging drug users who refused treatment[2].
Reasons for Not Getting Substance Use Treatment, 2025
| Reason given | Share citing it |
|---|---|
| Thought they should handle it on their own | 82.5% |
| Not ready to stop or cut back | 68.4% |
| Not ready to start treatment | 67.7% |
| Not enough time for treatment | 54.3% |
| Worried what people would think or say | 41.4% |
| Did not know how or where to get treatment | 40.5% |
| Thought treatment would cost too much | 39.2% |
| Feared losing job, home or children | 34.9% |
| Could not find a program or provider they wanted | 32.7% |
| Thought treatment would not help | 31.5% |
| Not enough insurance coverage | 30.4% |
People ages 12 and older with a perceived unmet need for substance use treatment who did not receive it, United States, 2025 (NSDUH)[8].
1Respondents could give more than one reason, so percentages add to more than 100.
Sources
- •SAMHSA, 2025 NSDUH
How to Talk to Someone About Their Drug Use
Federal treatment guidance treats mixed feelings about quitting as expected. SAMHSA's motivational counseling protocol, TIP 35, states that ambivalence about change is normal and that resistance is an expression of that ambivalence, not a fixed trait of the person[5].
The same 2019 guidance says confrontational approaches increase resistance and discord[5]. It was written for counselors, so its evidence comes from treatment settings rather than family conversations.
Word choice is part of the same picture. The National Institute on Drug Abuse (NIDA) recommends person-first language such as “person with a substance use disorder” instead of “addict,” “user” or “junkie,” and notes that feeling stigmatized can make people less willing to seek treatment[6].
NIDA also advises against calling drug test results “clean” or “dirty,” suggesting “testing negative” or “testing positive” instead, and notes that terms like “dirty” may decrease a person's sense of hope[6]. It flags “habit” because the word implies a person is choosing to use, and suggests “substance use disorder” instead[6].
More on how stigma works and how it is measured is in our explainer on stigma.
What If They Refuse Help? Family Training for Drug Use
Community Reinforcement and Family Training (CRAFT) works through a concerned family member or friend rather than the person using drugs, and teaches that family member behavior change skills[2].
The main drug-specific trial randomized 90 concerned significant others of treatment-refusing illicit drug users to CRAFT, CRAFT plus group aftercare, or Al-Anon and Nar-Anon facilitation therapy, each with 12 hours of manual-guided individual sessions[2].
CRAFT alone engaged 58.6% of the drug users in treatment, CRAFT plus aftercare engaged 76.7%, and the Al-Anon and Nar-Anon condition engaged 29.0%[2]. Follow-up rates for the family members were at least 96%[2].
One finding stands out for families: no participant engaged a treatment-refusing loved one after their own individual sessions had ended[2]. In this trial, engagement happened while the family member was still in active training.
The evidence has limits. This was one trial with 90 participants, published in 2002[2]. Trials of CRAFT for drinking, and its comparison with confrontational “Johnson-style” interventions, are covered in how to help someone with an alcohol addiction.
When Opioids Are Involved: Naloxone and Overdose Response
Overdose is the most immediate risk. Provisional CDC data show an estimated 69,973 U.S. drug overdose deaths in 2025, down almost 14% from 81,313 in 2024, with 44,564 of the 2025 deaths involving opioids[9].
Many of these deaths happen with someone nearby. CDC reports that a potential bystander was present in nearly 43% of overdose deaths in 2023[3].
Naloxone reverses overdoses from opioids, including fentanyl, heroin and prescription opioids, and can restore normal breathing within 2 to 3 minutes[3]. It comes as a nasal spray or injection, is available over the counter in all 50 states, and will not harm someone who is overdosing on drugs other than opioids[3].
CDC notes that more than one dose may be needed when fentanyl is involved, and advises staying with the person until emergency help arrives or for at least 4 hours[3]. It recommends that people with opioid use disorder keep naloxone at home and let others know they have it[3].
Good Samaritan laws in most states protect both the person overdosing and anyone assisting them from criminal penalties, according to CDC[3]. For how opioids slow breathing, see respiratory depression; for opioid-specific data, see opioid use disorder.
Which Treatments Work: Medications for Opioid Use Disorder
For opioid use disorder, the FDA has approved three medications, buprenorphine, methadone and naltrexone, and describes all three as safe and effective[7].
The three work differently. Methadone and buprenorphine both act on the brain's mu-opioid receptors and reduce cravings and withdrawal symptoms without producing intense feelings of pleasure in people with opioid use disorder; buprenorphine activates those receptors to a lesser degree and can block other opioids from attaching[10].
Naltrexone is typically started only after a person has completely stopped taking other opioids, because otherwise it may cause withdrawal symptoms[10]. NIDA reports that methadone and buprenorphine can be equally effective in helping people reduce opioid use, and that both help people stay in treatment[10].
Medications for alcohol use disorder are a separate set, covered in how to help someone with an alcohol addiction and on the alcohol use disorder data page.
Medications for opioid use disorder (MOUD)
The FDA-approved medications buprenorphine, methadone and naltrexone, used to treat opioid use disorder[7]. NIDA prefers “MOUD” to terms like “replacement therapy” or “medication-assisted treatment,” noting that it is a misconception that these medications substitute one addiction for another[6].
Related Terms
Source: U.S. Food and Drug Administration; National Institute on Drug Abuse
What the Mortality and Relapse Data Show
A 2017 meta-analysis in The BMJ pooled 19 cohorts covering 122,885 people treated with methadone and 15,831 treated with buprenorphine[4]. All-cause death rates were 11.3 per 1,000 person-years during methadone treatment and 36.1 after leaving it, and 4.3 versus 9.5 for buprenorphine[4].
The authors describe staying in treatment as associated with substantial reductions in all-cause and overdose deaths[4]. They flag the induction period at the start of methadone treatment and the time right after leaving either medication as periods of higher risk, and caution that confounding and selection bias may affect the comparisons[4].
Use remains low. In 2025, 15.7% of the 4.0 million people with opioid use disorder received medication for it, and 2.6% of the 25.7 million with alcohol use disorder received medication for that[1].
Relapse is common and not unique to addiction. NIDA puts relapse rates for substance use disorders at 40% to 60%, compared with 50% to 70% for hypertension and asthma[11]. It describes a return to use as a sign that treatment needs to be resumed, modified or replaced, not as proof that treatment failed[11].
Supporting Recovery and Caring for the Helper
Recovery is common over time. In 2025, 30.6 million U.S. adults said they had ever had a problem with drugs or alcohol, and 73.0% of them considered themselves in recovery or recovered[1].
For finding care, SAMHSA's National Helpline, 1-800-662-HELP (4357), is a free, confidential, 24/7 referral service in English and Spanish for individuals and family members[12]. It refers callers to local treatment facilities, support groups and community organizations but does not provide counseling[12].
The helpline received 833,598 calls in 2020, the most recent year listed on its site[12]. SAMHSA also points families to FindTreatment.gov to locate treatment facilities and providers[1].
Mutual-help groups such as Al-Anon and Nar-Anon exist for relatives. In the 2002 CRAFT trial, a facilitation program built around them was the comparison condition and engaged fewer drug users in treatment than CRAFT, though the trial measured treatment entry, not the family member's own well-being[2].
For data on the health of people caring for a relative, see carer mental health and the family caregivers data page.
Frequently Asked Questions
Sources & References
- Substance Abuse and Mental Health Services Administration. SAMHSA Releases Annual National Survey on Drug Use and Health. U.S. Department of Health and Human Services. Published 2026. Accessed October 2026. https://www.samhsa.gov/newsroom/press-announcements/20260727/samhsa-releases-annual-national-survey-on-drug-use-and-health [Link]
- Meyers RJ, Miller WR, Smith JE, Tonigan JS. A randomized trial of two methods for engaging treatment-refusing drug users through concerned significant others. Journal of Consulting and Clinical Psychology. Published 2002. Accessed October 2026. https://pubmed.ncbi.nlm.nih.gov/12362968/ [Link]
- Centers for Disease Control and Prevention. Lifesaving Naloxone. U.S. Department of Health and Human Services. Published 2025. Accessed October 2026. https://www.cdc.gov/stop-overdose/caring/naloxone.html [Link]
- Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. Published 2017. Accessed October 2026. https://www.bmj.com/content/357/bmj.j1550 [Link]
- Substance Abuse and Mental Health Services Administration. Enhancing Motivation for Change in Substance Use Disorder Treatment (Treatment Improvement Protocol Series No. 35). SAMHSA Publication No. PEP19-02-01-003. Published 2019. Accessed October 2026. https://library.samhsa.gov/sites/default/files/tip-35-pep19-02-01-003.pdf [Link]
- National Institute on Drug Abuse. Words Matter: Preferred Language for Talking About Addiction. National Institutes of Health. Published 2021. Accessed October 2026. https://nida.nih.gov/research-topics/addiction-science/words-matter-preferred-language-talking-about-addiction [Link]
- U.S. Food and Drug Administration. Information about Medications for Opioid Use Disorder (MOUD). U.S. Department of Health and Human Services. Published 2024. Accessed October 2026. https://www.fda.gov/drugs/food-and-drug-administration-overdose-prevention-framework/information-about-medications-opioid-use-disorder-moud [Link]
- Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2025 National Survey on Drug Use and Health. Center for Behavioral Health Statistics and Quality. Published 2026. Accessed October 2026. https://www.samhsa.gov/data/sites/default/files/reports/rpt57150/2025-nsduh-annual-national-html/2025-nsduh-annual-national.htm [Link]
- National Center for Health Statistics. U.S. Overdose Deaths Decrease for Third Consecutive Year in 2025. Centers for Disease Control and Prevention. Published 2026. Accessed October 2026. https://www.cdc.gov/nchs/pressroom/releases/20260513.html [Link]
- National Institute on Drug Abuse. Medications for Opioid Use Disorder. National Institutes of Health. Published 2025. Accessed October 2026. https://nida.nih.gov/research-topics/medications-opioid-use-disorder [Link]
- National Institute on Drug Abuse. Treatment and Recovery. Drugs, Brains, and Behavior: The Science of Addiction. National Institutes of Health. Published 2020. Accessed October 2026. https://nida.nih.gov/publications/drugs-brains-behavior-science-addiction/treatment-recovery [Link]
- Substance Abuse and Mental Health Services Administration. SAMHSA's National Helpline. U.S. Department of Health and Human Services. Published 2026. Accessed October 2026. https://www.samhsa.gov/find-help/helplines/national-helpline [Link]